Genmab A/S (OTCMKTS:GNMSF – Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 206,200 shares, an increase of 11.1% from the August 15th total of 185,600 shares. Based on an average trading volume of 1,800 shares, the short-interest ratio is presently 114.6 days.
Genmab A/S Price Performance
Shares of GNMSF opened at $259.32 on Wednesday. Genmab A/S has a one year low of $241.09 and a one year high of $381.93. The company has a market cap of $16.95 billion, a PE ratio of 21.47 and a beta of 1.07. The stock has a 50-day moving average of $268.44 and a 200-day moving average of $277.33.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.13 earnings per share for the quarter. The firm had revenue of $779.50 million for the quarter. Genmab A/S had a net margin of 29.06% and a return on equity of 20.60%.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
- Five stocks we like better than Genmab A/S
- What is Forex and How Does it Work?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- The Most Important Warren Buffett Stock for Investors: His Own
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- EV Stocks and How to Profit from Them
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
